Antigen News and Research

RSS

Moderna's COVID vaccine proves effective against South African variant in primates

Researchers in the United States have demonstrated the efficacy of Moderna’s coronavirus disease 2019 (COVID-19) vaccine at protecting against the South African B.1.351 variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in non-human primates.

26 May 2021

NFCR announces winners of 2021 Salisbury Award Competition

The National Foundation for Cancer Research (NFCR) announced winners of the 2021 Salisbury Award Competition for Entrepreneurial Translational Research, selected from among eight semi-finalists after pitch presentations in front of a judging committee consisting of prominent cancer research scientists, clinicians, early-stage investors and business leaders.

26 May 2021

Study attempts to standardize humoral immune Correlates of Protection (CoP) in COVID-19

A new study aims to identify antibody-based biomarkers associated with the humoral immune response that could be a standard CoP candidate for COVID-19. Further, standardization of research methods to measure these biomarkers has also been conducted.

25 May 2021

Human T cells can target more than 1,400 sites on SARS-CoV-2 virus

In a new paper, scientists from La Jolla Institute for Immunology (LJI) bring together research findings from COVID-19 researchers around the world.

25 May 2021

Next-generation SARS-CoV-2 subunit vaccine candidate elicits powerful immunity in preclinical trials

New research – by scientists at the University of Chicago, Johns Hopkins School of Medicine and the University of Iowa in the USA – describes a novel COVID-19 vaccine candidate that has achieved impressive immunologic results in mouse studies.

25 May 2021

SARS-CoV-2 UK variant may induce more inflammation, study suggests

Since COVID-19 was first detected in December 2019 in Wuhan, China, many different variants of its causative virus – SARS-CoV-2 – have emerged. Through increased viral fitness, some of these have risen to predominance over earlier variants in a remarkably short period of time. New research, by a team of scientists at major institutions in France, examines the reasons behind this phenomenon in one such variant of concern (VOC), the so-called UK variant.

25 May 2021

New testing protocol for SARS-CoV-2 can process thousands of samples within 48 hours

Researchers at the Vienna BioCenter designed a testing protocol for SARS-CoV-2 that can process tens of thousands of samples in less than 48 hours. The method, called SARSeq, is published in the journal Nature Communications and could be adapted to many more pathogens.

25 May 2021

Researchers take steps to standardize correlates of protection against SARS-CoV-2

Antibodies, Antibody, Assay, Coronavirus, Efficacy, Healthcare, Pandemic, Protein, Receptor, Research, Vaccine, Virus, Coronavirus Disease COVID-19,

24 May 2021

Researchers identify aluminum hydroxide/TLR9 agonist as potential adjuvant to improve RBD-based COVID-19 vaccine efficacy

The study findings reveal that RBD-based vaccines adjuvanted with the formulation can induce strong anti-SARS-CoV-2 neutralizing immunity in young and aged mice. The study is currently available on the bioRxiv* preprint server.

24 May 2021

Memory B cells with a functional anti-SARS-CoV-2 response persist despite loss of specific IgG

In Munich, Germany, scientists at Ludwig Maximilian University studied temporal adaptive immunity to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to better understand protection against re-infection. They found functional properties of persisting memory B specific to SARS-CoV-2 may help in protect against the virus.

23 May 2021

When COVID-19 is severe, rogue antibodies attack body tissues and organs

The study, published in the journal Nature, sheds light on the disease mechanism of COVID-19 and how the virus causes a faulty immune system.

21 May 2021

Pfizer-BioNTech vaccination not associated with platelet activation in new study

Among the devastating complications of severe or critical coronavirus disease 2019 (COVID-19), clot formation ranks high in the adverse impact it creates. An important question is whether SARS-CoV-2-spike-based vaccines also cause such coagulopathies. A new study, released as a preprint on the medRxiv* server, examines this risk for the first time.

21 May 2021

Risk factors for rare COVID-19 complications in children (MIS-C)

While the earlier waves of COVID-19 relatively spared children, some of the affected children have developed a systemic inflammatory condition, with occasionally fatal outcomes. Called multisystem inflammatory syndrome in children (MIS-C), its pathogenesis and risk factors are the subject of a new study on the medRxiv* preprint server.

21 May 2021

Facets of SARS-CoV-2 infection and animal models

A new study in the journal Frontiers in Cell and Developmental Biology discusses the ribonucleic acid (RNA) genome of the virus, and the mechanisms by which it establishes infection within the host cell. The researchers also summarize the development of animal models of COVID-19, which will both help understand the clinical features of the illness, and indicate new approaches for the treatment of the infection.

21 May 2021

Adaptimmune to report Phase 2 trial data on synovial sarcoma at ASCO congress

Adaptimmune Therapeutics plc, a leader in cell therapy to treat cancer, will report initial data from its Phase 2 SPEARHEAD-1 trial, with afamitresgene autoleucel (afami-cel, formerly ADP-A2M4), at the American Society of Clinical Oncology (ASCO) congress. Full abstracts were released online today.

21 May 2021

Tokyo sees rapid rise of SARS-CoV-2 R.1 lineage

A new research paper posted to the preprint server medRxiv* reports the rise of a new lineage in Tokyo, Japan, bearing a combination of two biologically important mutations.

20 May 2021

Are COVID-19-related complications in children explained by abnormal immune responses?

A common theme in reports on COVID-19 around the world has been the large number of children who have not been infected or shown signs of disease. However, though the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes less acute infection in this age group, it is associated with a severe immune-mediated multisystemic illness called multisystem inflammatory syndrome in children (MIS-C).

20 May 2021

Plant-produced COVID-19 vaccine shows potent immunogenic profile in humans

An interim report on a phase 2 clinical trial indicates both the safety and efficacy of a plant-produced virus-like particle vaccine candidate against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The vaccine candidate has shown an acceptable safety profile and high potency in inducing humoral and cellular immune responses in adults (18 – 64 years) and elderly (65 years and above) individuals. The report is currently available on the medRxiv* preprint server.

20 May 2021

Monoclonal antibody bamlanivimab reduces hospitalization and death in moderate-to-severe COVID-19

Researchers at the University of Pittsburgh School of Medicine and the University of Pittsburgh Medical Center found that monoclonal antibodies, a COVID-19 treatment administered early after infection, reduce the risk of hospitalization and death by 60 percent in people at high risk of suffering complications from the condition.

20 May 2021

Protein-based vaccines against SARS-CoV-2 may provide advantages over mRNA-based vaccines

Researchers in the UK have developed a protein-based subunit vaccine directed against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that could serve as an alternative to the mRNA-based vaccines currently approved for protecting against coronavirus disease 2019 (COVID-19).

20 May 2021

Antigen News and Research

Moderna's COVID vaccine proves effective against South African variant in primates

NFCR announces winners of 2021 Salisbury Award Competition

Study attempts to standardize humoral immune Correlates of Protection (CoP) in COVID-19

Human T cells can target more than 1,400 sites on SARS-CoV-2 virus

Next-generation SARS-CoV-2 subunit vaccine candidate elicits powerful immunity in preclinical trials

SARS-CoV-2 UK variant may induce more inflammation, study suggests

New testing protocol for SARS-CoV-2 can process thousands of samples within 48 hours

Researchers take steps to standardize correlates of protection against SARS-CoV-2

Researchers identify aluminum hydroxide/TLR9 agonist as potential adjuvant to improve RBD-based COVID-19 vaccine efficacy

Memory B cells with a functional anti-SARS-CoV-2 response persist despite loss of specific IgG

When COVID-19 is severe, rogue antibodies attack body tissues and organs

Pfizer-BioNTech vaccination not associated with platelet activation in new study

Risk factors for rare COVID-19 complications in children (MIS-C)

Facets of SARS-CoV-2 infection and animal models

Adaptimmune to report Phase 2 trial data on synovial sarcoma at ASCO congress

Tokyo sees rapid rise of SARS-CoV-2 R.1 lineage

Are COVID-19-related complications in children explained by abnormal immune responses?

Plant-produced COVID-19 vaccine shows potent immunogenic profile in humans

Monoclonal antibody bamlanivimab reduces hospitalization and death in moderate-to-severe COVID-19

Protein-based vaccines against SARS-CoV-2 may provide advantages over mRNA-based vaccines

Industry Focus eBook - Analytical Chemistry (2nd Edition) eBook

Latest eBooks

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics